Vontobel Holding Ltd. Sells 28,574 Shares of BioNTech SE (NASDAQ:BNTX)

Vontobel Holding Ltd. decreased its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 62.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,158 shares of the company's stock after selling 28,574 shares during the quarter. Vontobel Holding Ltd.'s holdings in BioNTech were worth $2,038,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company's stock worth $25,000 after purchasing an additional 150 shares during the period. Covestor Ltd boosted its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company's stock valued at $38,000 after acquiring an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after acquiring an additional 252 shares during the last quarter. Crewe Advisors LLC acquired a new stake in BioNTech during the 1st quarter worth about $75,000. Finally, Daiwa Securities Group Inc. raised its position in shares of BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock worth $155,000 after acquiring an additional 1,562 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BNTX shares. Deutsche Bank Aktiengesellschaft upped their target price on BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. HC Wainwright raised their price objective on shares of BioNTech from $113.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Hsbc Global Res upgraded shares of BioNTech from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 2nd. UBS Group increased their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 18th. Finally, Bank of America lifted their price target on shares of BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $131.92.

BioNTech Stock Down 2.4 %

BNTX stock traded down $2.70 during mid-day trading on Friday, reaching $111.77. 1,320,106 shares of the company traded hands, compared to its average volume of 789,240. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The firm's 50 day moving average price is $104.56 and its 200 day moving average price is $94.20. The stock has a market cap of $26.57 billion, a price-to-earnings ratio of 223.54 and a beta of 0.24. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analysts' expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm's quarterly revenue was down 23.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.86) EPS. As a group, equities research analysts predict that BioNTech SE will post -3.04 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.